OGN

Handel nachbörslich: 16.41 -0.05 -0.30%

Organon Co (OGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Organon Co Stock (OGN) Company Profile

Healthcare (1182)

551-430-6000

30 HUDSON STREET, JERSEY CITY

Nächster Verdiensttermin

Neueste SEC-Einreichungen

OGN's Discussions on Twitter

Organon Co Stock (OGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-06	Herabstufung	JP Morgan	Neutral → Underweight
2023-11-03	Herabstufung	Goldman	Buy → Neutral
2023-09-21	Eingeleitet	Barclays	Overweight
2023-03-16	Eingeleitet	Raymond James	Outperform
2022-10-14	Herabstufung	BofA Securities	Neutral → Underperform
2022-09-06	Hochstufung	Piper Sandler	Neutral → Overweight
2022-08-05	Herabstufung	BofA Securities	Buy → Neutral
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-10-07	Eingeleitet	Piper Sandler	Neutral
2021-09-01	Eingeleitet	BofA Securities	Buy
2021-07-22	Eingeleitet	Citigroup	Buy
2021-06-15	Eingeleitet	JP Morgan	Neutral
2021-06-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-06-10	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

Organon Co Aktie (OGN) Neueste Nachrichten

Finanzdaten der Organon Co-Aktie (OGN)

Organon Co (OGN)

Organon Co Stock (OGN) Company Profile

Organon Co Stock (OGN) Upgrades & Downgrades

Organon Co Aktie (OGN) Neueste Nachrichten

Organon & Co. (NYSE:OGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance

Relative Strength Alert For Organon - Nasdaq

Organon updates outlook as FDA delays VTAMA label expansion - MSN

Organon reports FDA extension of target action date of review of Vtama sNDA - TipRanks

Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks

Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha

FDA extends Organon's VTAMA cream review to March 2025 - Investing.com

Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com

Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com UK

Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St

Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle

(OGN) Technical Pivots with Risk Controls - Stock Traders Daily

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance

Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN

Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance

Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat

Organon & Co (OGN) Shares Up 5.61% on Oct 31 - GuruFocus.com

Organon: Q3 Earnings Snapshot - The Advocate

Organon & Co. Reports Strong Third Quarter 2024 Results - TipRanks

Organon Co earnings missed by $0.03, revenue topped estimates - Investing.com Australia

Organon (OGN) Q3 Earnings and Revenues Beat Estimates - MSN

Earnings call: Organon announced a revenue of $1.6 billion - Investing.com

Earnings call: Organon announced a revenue of $1.6 billion By Investing.com - Investing.com UK

Organon Reports Results for the Third Quarter Ended September 30, 2024 - BioSpace

Organon & Co Q3 2024 Earnings: EPS Soars to $1.38, Revenue Hits $1.582 Billion, Surpassing Estimates - GuruFocus.com

Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Organon Q3 2024 Earnings Preview: Dermavant purchase in focus - MSN

FDA accepts Henlius and Organon's biosimilar application By Investing.com - Investing.com South Africa

Organon Q3 2024 Earnings Preview: Dermavant purchase in focus (NYSE:OGN) - Seeking Alpha

FDA accepts Organon BLA for Prolia/Xgeva biosimilar (NYSE:OGN) - Seeking Alpha

FDA accepts Henlius and Organon's biosimilar application - Investing.com

Dermavant acquisition expands Organon’s dermatology portfolio - MSN

Organon Completes Acquisition of Dermavant - citybiz

Organon completes Dermavant Sciences acquisition - Investing.com

Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com UK

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan

Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

Organon & Co. (NYSE:OGN) Short Interest Up 28.2% in October - MarketBeat

Do Options Traders Know Something About Organon (OGN) Stock We Don't? - MSN

Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline - Yahoo Finance

Organon & Co trades in the red for seven straight sessions - MSN

Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga

Organon (Thailand) Ltd. promotes health and elevates women’s quality of life, creating change at the WEPs Awards 2024 - Nation Thailand

Organon (OGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance

YieldBoost Organon From 6.4% To 11.4% Using Options - Nasdaq

With 80% institutional ownership, Organon & Co. (NYSE:OGN) is a favorite amongst the big guns - Simply Wall St

Finanzdaten der Organon Co-Aktie (OGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie OGN